HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
申请人:Asana Biosciences, LLC
公开号:US20160362407A1
公开(公告)日:2016-12-15
The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R
1
to R
8
are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
具有以下化学式(I)的化合物以及它们的使用和制备方法已被披露:
[EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
申请人:NUVATION BIO INC
公开号:WO2020210383A1
公开(公告)日:2020-10-15
Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
The present invention relates to a phenoxypropylamine compound of the formula (I)
1
wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT
1A
receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.
[EN] PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR<br/>[FR] DÉRIVÉ DE PYRAZOLO[3,4-D]PYRIMIDINE-3-CÉTONE UTILISÉ EN TANT QU'INHIBITEUR DE WEE-1<br/>[ZH] 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物